Carlsmed aprevo® Wins Spine Technology Award
“The Carlsmed team is honored to accept this award from Orthopedics This Week for our breakthrough aprevo® technology,” said Mike Cordonnier, CEO of Carlsmed. “Our mission is to provide broad access to this technology for patients suffering from debilitating spinal disorders.”
The aprevo® patient-specific interbody fusion devices are made possible by Carlsmed’s proprietary Data to Device™ digital technologies. For each aprevo® patient, a personalized surgical plan is developed preoperatively and presented to the surgeon to achieve the optimal spinal alignment target. Upon approval of the plan, unique interbody devices are created for the patient to address their specific pathology.
"By intentionally creating implants to fit a patient's own bone, we can start to realize the potential of personalized medicine and its benefits to each individual patient,” says Vijay Yanamadala, M.D., neurosurgeon and Director of Spinal Deformity Surgery at Hartford HealthCare. “My goal is for the aprevo® surgery to be the last spine surgery that a patient will ever need.”
The aprevo® patient specific interbody fusion devices are currently 510(k) cleared by the FDA for commercial use in the US for anterior, lateral and transforaminal surgical approaches.
Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company’s aprevo® devices are designed to improve the standard of care for the surgical treatment of adult patients with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices to align with the surgeon’s goals for each patient.